Group 1 - The company BoHui Innovation announced the convening of its 8th Board of Directors meeting on August 27, 2025, to review the "2025 Semi-Annual Report" and its summary [1] Group 2 - The news highlights the world's first successful transplantation of gene-edited pig lungs into a human, raising questions about the timeline for clinical applications [1]

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-032 北京博晖创新生物技术集团股份有限公司 关于计提资产减值准备及核销资产的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 于 2025 年 8 月 27 日召开第八届董事会第十三次会议和第八届监事会第十二次会 议，审议通过了《关于计提资产减值准备及核销资产的议案》，同意计提资产减 值准备及核销资产，其中，计提资产减值准备合计金额人民币 2,514,850.40 元； 核销资产合计金额人民币 2,678,304.72 元。现将具体情况公告如下： 一、本次计提资产减值准备基本情况 （一）本次计提资产减值准备概况 1、本次计提资产减值准备的原因 为真实反映公司财务状况和经营成果，公司依据《企业会计准则第8号—资 产减值》规定，基于谨慎性原则，对截至2025年6月30日公司及合并范围内各下 属公司所属资产进行了减值测试，判断存在减值的迹象，确定了需要计提减值准 备的资产项目。 2、本次计提资产减值准备的范围和金额 项目 ...

北京博晖创新生物技术集团股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 注：①表中非经营性占用部分，关联方范围依照《创业板上市规则》确定。②无控股股东、实际控制人的公司，存在第一大股东或第一大股东关联人非经营性占用资金的，也应填写本表非经营性占用部分。 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算 | 2025 年年初占 | 2025 年 1-6 月占 用累计发生金额 | 2025 年 1-6 月 占用资金的利 | 2025年1-6月 偿还累计发 | 2025 年 6 月末 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 的会计科目 | 用资金余额 | （不含利息） | 息（如有） | 生金额 | 占用资金余额 | 原因 | | | 控股股东、实际控 | | | | | | | | | | 非经营性占用 | | 制人及其附属企业 | | | | | | | | | | 非经营性占用 | ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-031 1、审议通过《<2025 年半年度报告>及其摘要》 监事会认为：公司结合 2025 年半年度的实际经营管理情况编制的《<2025 年 半年度报告>及其摘要》符合《深圳证券交易所创业板股票上市规则》、《上市公司 信息披露管理办法》等法律法规的相关要求。其内容真实、准确、完整的反映了公 司 2025 年半年度的经营管理情况，不存在虚假记载、误导性陈述或重大遗漏。该 报告未经会计师事务所审计。 北京博晖创新生物技术集团股份有限公司 第八届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"）第 八届监事会第十二次会议于 2025 年 8 月 27 日在公司会议室召开，会议通知于 2025 年 8 月 15 日以专人送达、邮件通知或电话通知的方式送达各位监事。会议由 公司监事会主席杜江虹女士主持，会议采取现场和通讯表决相结合方式进行，本次 会议应出席监事 3 人，实际出席监事 3 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-030 北京博晖创新生物技术集团股份有限公司 第八届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 第八届董事会第十三次会议于 2025 年 8 月 27 日在公司会议室召开，会议通知于 2025 年 8 月 15 日以专人送达、邮件通知或电话通知的方式送达各位董事，会议 由公司董事长沈治卫先生主持，会议采取现场和通讯表决相结合方式进行，本次 会议应出席董事 7 人，实际出席董事 7 人，监事和高级管理人员列席了会议。本 次会议的召集召开程序符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 本次会议审议通过了以下议案： 1、审议通过《<2025 年半年度报告>及其摘要》 同意公司根据《深圳证券交易所创业板股票上市规则》、《公开发行证券的公 司信息披露内容与格式准则第 3 号——半年度报告的内容与格式》等法律法规的 相关要求，结合本公司 2025 年上半年的 ...

Financial Performance - The company's operating revenue for the first half of 2025 was ¥403,960,042.20, a decrease of 17.03% compared to ¥486,888,926.66 in the same period last year[18] - The net profit attributable to shareholders of the listed company was -¥18,688,204.59, representing a decline of 167.63% from ¥27,633,766.56 in the previous year[18] - The net cash flow from operating activities was -¥50,613,850.12, a significant drop of 388.83% compared to ¥17,523,461.09 in the same period last year[18] - The basic earnings per share were -¥0.0229, down 167.75% from ¥0.0338 in the previous year[18] - The company reported a significant increase in cash and cash equivalents, with a net increase of 592.25% to ¥91,804,021.47[58] - The company reported a total comprehensive loss of CNY 30,105,785.85 for the first half of 2025, contrasting with a comprehensive income of CNY 56,026,235.20 in the prior year[169] - The company reported a net loss of CNY 217,971,925.74, compared to a loss of CNY 199,283,721.15 in the previous period[164] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,316,123,512.54, an increase of 4.62% from ¥4,125,558,100.42 at the end of the previous year[18] - The total amount of guarantees at the end of the reporting period was 236,500,000 CNY, with actual guarantee balances totaling 92,958,230 CNY[133] - Total liabilities increased to CNY 1,997,100,759.06 from CNY 1,776,429,561.09, marking a rise of approximately 12.4%[164] - The company's total equity decreased to CNY 1,360,384,587.77 from CNY 1,378,686,990.40, a decline of about 1.3%[164] Revenue Streams - The company’s inspection and testing business achieved a main operating revenue of 99.61 million yuan, a year-on-year decrease of 16.79%[31] - Revenue from in vitro diagnostic products was 47.90 million yuan, down 38.14% compared to the previous year, while non-medical testing products revenue increased by 22.34% to 51.71 million yuan[31] - The company’s biopharmaceutical business achieved main operating revenue of 286.66 million yuan, a year-on-year decrease of 18.33% due to reduced demand for blood products and lower sales volume[45] Research and Development - The company has initiated a strategic partnership with F to enhance its product offerings and market reach[36] - The company is actively involved in the research and development of innovative medical devices to enhance its market position[33] - Research and development investment decreased by 9.87% to ¥35,963,544.34, indicating a focus on cost management[58] - The company is focused on expanding its product line with new technologies and medical devices to enhance diagnostic capabilities[39] Product Development and Registration - The company has a total of 53 medical device registration certificates as of June 30, 2024, with 1 certificate canceled and 2 renewed during the first half of 2024[32] - The company is currently in the registration application phase for several medical devices, including a nucleic acid detection kit for reproductive tract pathogens, which is in the clinical conclusion stage[40] - The company has developed a fluorescence immunoassay analyzer for quantitative detection of substances in human samples, with a registration valid until December 2029[33] Market Strategy - The company has established long-term stable partnerships with multiple distributors across the country, enhancing its market position through innovative technology[29] - The company's strategy includes building a customer network through instrument sales and driving reagent sales via technical services[29] - The company is expanding its market presence with plans to enter D new regions by the end of the fiscal year[36] Financial Management - The company has established a strong quality management system, achieving certifications such as GMP, ISO13485, and ISO9001[53] - The company has maintained a focus on the health industry, emphasizing technological innovation and strategic expansion[50] - The company is seeking a comprehensive financing credit limit of up to RMB 2 billion from banks and financial institutions[141] Shareholder Information - The total number of shares after the recent changes is 816,900,495, with 2.25% being limited shares and 97.75% being unrestricted shares[148] - The largest shareholder, Du Jiangtao, holds 39.03% of the shares, totaling 318,811,388 shares[150] - The total number of shareholders at the end of the reporting period is 31,104[150] Compliance and Regulations - The company adheres to the regulations set by the National Medical Products Administration for its medical devices[33] - The company has not reported any changes in accounting policies or prior period error corrections during this reporting period[191] - The company’s blood products are subject to batch release management, ensuring compliance with regulatory standards before market release[43]

Group 1 - The A-share biopharmaceutical sector experienced a short-term surge, with Tian Tan Biological reaching the daily limit, and Wan Ze Shares previously hitting the limit as well [1] - Other companies such as Aidi Pharmaceutical, Zhifei Biological, Boya Biological, Bohui Innovation, and Pailin Biological also saw increases in their stock prices [1] - The news is driven by the completion of China's first copy-type Tian Tan smallpox vaccine carrier HIV vaccine Phase I clinical trial by teams from the Chinese Center for Disease Control and Prevention and the AIDS Prevention Center [1]

Group 1 - The biopharmaceutical sector experienced a short-term surge, with TianTan Bio reaching the daily limit increase [1] - WanZe Co. previously hit the limit up, indicating strong market interest [1] - Other companies such as Aidi Pharmaceutical, ZhiFei Biological, BoYa Bio, BoHui Innovation, and PaiLin Bio also saw significant gains [1]

Core Insights - The report highlights that the total salary of A-share listed company secretaries reached 4.086 billion yuan in 2024, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for company secretaries in the A-share biopharmaceutical sector is 1.01 million yuan [5] - The distribution of salaries shows that 15% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 38% earn between 1 million and 2 million yuan, 4% earn between 2 million and 3 million yuan, and 2% earn above 3 million yuan [5] Age and Educational Background - The majority of company secretaries (61%) are aged between 40 and 50 years, while 15% are over 50, 18% are between 30 and 40, and 6% are 30 or younger [1] - In terms of education, 52% hold a bachelor's degree, 44% have a master's degree, and only 2% have a doctoral degree, with master's and above accounting for over half of the total [3] Investor Engagement - There is a wide variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually, while only 2% have more than 1,000 meetings [7] - The top five companies with the highest number of investor meetings include Bohui Innovation, Jindike, Nearshore Protein, Sailun Biotech, and Kanghua Biotech, with meeting counts of 1,500, 777, 681, 549, and 504 respectively [9]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 secretaries earned over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for secretaries in the A-share biopharmaceutical sector is 1.01 million yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] Age and Education Distribution - The age distribution of secretaries shows that those aged 40-50 constitute 61%, while those over 50 account for 15%, and those aged 30-40 make up 18% [1] - In terms of education, 52% of secretaries hold a bachelor's degree, while 44% have a master's degree, and only 2% possess a doctoral degree [3] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [7] - The top five companies with the highest number of investor meetings are: Bohui Innovation (1,500 meetings), Jindike (777 meetings), Nearshore Protein (681 meetings), Sailun Biotech (549 meetings), and Kanghua Biotech (504 meetings) [9]